Immuno-oncology specialist Agenus (Nasdaq: AGEN) has announced the selection of a lead product candidate under its license and research collaboration with Merck & Co (NYSE: MRK).
Agenus develops antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines.
Merck has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed checkpoint target and based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze